SCHEMBL7900323

SCHEMBL7900323

CCCC(=O)NC(C)c1ccc(Cl)cc1

nearest known ligand 0.57

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ACACA Q13085 2/20 0.56
MEN1 O00255 2/20 0.55
KMT2A Q03164 2/20 0.55
GPR139 Q6DWJ6 5/20 0.52
PRCP P42785 1/20 0.52
SMN1; SMN2 Q16637 2/20 0.51
GAA P10253 1/20 0.51
HPGD P15428 1/20 0.51
MAPT P10636 1/20 0.50
CNR1 P21554 1/20 0.49
ALDH1A1 P00352 1/20 0.49
LMNA P02545 1/20 0.49
HTT P42858 1/20 0.49
ACACB O00763 2/20 0.47
KDM4E B2RXH2 1/20 0.47
POLB P06746 1/20 0.47
HSP90AA1 P07900 1/20 0.47
RAB9A P51151 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7681216 0.90 MEN1 (0.59) ACACAMEN1KMT2AGPR139PRCP
SCHEMBL7677571 0.90 MEN1 (0.59) ACACAMEN1KMT2AGPR139PRCP
SCHEMBL8949273 0.90 SMN1; SMN2 (0.53) MEN1KMT2AGPR139PRCPSMN1; SMN2
SCHEMBL8445815 0.86 GPR139 (0.55) ACACAMEN1KMT2AGPR139PRCP
SCHEMBL15200212 0.85 ACACA (0.57) ACACAGPR139HPGDMAPTCNR1
SCHEMBL12768105 0.84 PRCP (0.54) ACACAMEN1KMT2APRCPGAA
SCHEMBL7897298 0.83 SMN1; SMN2 (0.69) MEN1KMT2AGPR139PRCPSMN1; SMN2
SCHEMBL16975095 0.83 MAPT (0.71) ACACAMEN1KMT2AGPR139GAA
SCHEMBL18241727 0.83 MAPT (0.71) ACACAMEN1KMT2AGPR139GAA
SCHEMBL23122290 0.81 GPR139 (0.54) MEN1KMT2AGPR139PRCPSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3452453-B1 MODULATORS OF THE INTEGRATED STRESS PATHWAY CALICO LIFE SCIENCES LLC (US) 2022-04-13 EP disclosed
US-8377639-B2 Compounds for modulating RNA binding proteins and uses therefor UNIVERSITY OF MASSACHUSETTS (US) 2013-02-19 US disclosed
US-20110065704-A1 COMPOUNDS FOR MODULATING RNA BINDING PROTEINS AND USES THEREFOR NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2011-03-17 US disclosed
US-6187582-B1 REACTING RACEMIC AMINE AND ESTER IN PRESENCE OF LIPASE FROM CANDIDA ANTARCTICA AND DILUENT, SEPARATING MIXTURE OF (S)-AMINE, SEPARATING THE ACYLATED (R)-AMINE, THEN OPTIONALLY DEACYLATING THE (R)-AMINE BY TREATMENT WITH AN ACID OR BASE BAYER AKTIENGESELLSCHAFT (DE) 2001-02-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065704-A1 COMPOUNDS FOR MODULATING RNA BINDING PROTEINS AND USES THEREFOR TIA1, ZFP3, RBM3 ACACA 3984/4885MEN1 1444/4885KMT2A 3013/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.